HalioDx, a Marseille, France-based diagnostic company expert in the analysis of the tumor microenvironment, closed a €18.5m Series B financing.
Backers included PSIM fund (managed by Bpifrance in the framework of the program ‘Investing for the Future’), Quest for Growth (managed by Capricorn venture Partners and Amundi Private Equity Funds), and historical investors MI Care S.A., Sham Innovation Santé/Turenne, BNP Paribas Development and Sofipaca.
The company intends to use the funds to accelerate the development of Immunoscore® for colon cancer and selected additional cancer types and set up commercial activities in the US.
Led by Vincent Fert, CEO, HalioDx operates Immunoscore, a diagnostic platform based on the analysis of the tumor microenvironment combining immunohistochemistry and advanced digital pathology to guide oncologists in optimizing the management of their patients. In colon cancer, the company has already accumulated a strong body of clinical evidence in predicting individual risk of recurrence and is progressing toward reimbursement decisions for Immunoscore in several countries.
In parallel, HalioDx developed a significant immune biomarker partnering program with Biopharma to assess the predictive value of Immunoscore and other proprietary assays, notably Immunosign® and Halioseek®. These studies are conducted in the context of various therapeutic modalities and in multiple indications, including companion diagnostics approaches for specific immunotherapies.
The company has a team of more than 130 employees, a CLIA laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products.